These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 17957826)
1. Complications and side effects. Bone changes after starting HAART. TreatmentUpdate; 2007; 19(5):6-7. PubMed ID: 17957826 [No Abstract] [Full Text] [Related]
2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
3. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019 [TBL] [Abstract][Full Text] [Related]
4. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D; AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330 [TBL] [Abstract][Full Text] [Related]
5. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765 [TBL] [Abstract][Full Text] [Related]
6. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564 [TBL] [Abstract][Full Text] [Related]
7. Complications & side effects. HAART and bones-mixed messages. TreatmentUpdate; 2007; 19(4):3-5. PubMed ID: 17969257 [No Abstract] [Full Text] [Related]
8. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity. Haddow LJ; Wood CW; Ainsworth JG Int J STD AIDS; 2007 May; 18(5):343-6. PubMed ID: 17524198 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro. Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients]. Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579 [TBL] [Abstract][Full Text] [Related]
11. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Chu JH; Gange SJ; Anastos K; Minkoff H; Cejtin H; Bacon M; Levine A; Greenblatt RM Am J Epidemiol; 2005 May; 161(9):881-90. PubMed ID: 15840621 [TBL] [Abstract][Full Text] [Related]
12. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A; Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566 [TBL] [Abstract][Full Text] [Related]
13. Complications & side effects. Nukes and fat wasting. TreatmentUpdate; 2004; 16(7):3-4. PubMed ID: 17225282 [No Abstract] [Full Text] [Related]
14. Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. Moreno-Pérez O; Escoín C; Serna-Candel C; Picó A; Alfayate R; Merino E; Reus S; Boix V; Sanchez-Paya J; Portilla J AIDS; 2010 Jan; 24(2):255-64. PubMed ID: 19915446 [TBL] [Abstract][Full Text] [Related]
15. Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy. Ridolfo AL; Gervasoni C; Bini T; Galli M AIDS Patient Care STDS; 2000 Nov; 14(11):595-601. PubMed ID: 11155901 [TBL] [Abstract][Full Text] [Related]
16. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects. Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202 [No Abstract] [Full Text] [Related]
18. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038 [No Abstract] [Full Text] [Related]
19. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254 [TBL] [Abstract][Full Text] [Related]
20. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]